LT3386591T - Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas - Google Patents
Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimasInfo
- Publication number
- LT3386591T LT3386591T LTEP16820103.6T LT16820103T LT3386591T LT 3386591 T LT3386591 T LT 3386591T LT 16820103 T LT16820103 T LT 16820103T LT 3386591 T LT3386591 T LT 3386591T
- Authority
- LT
- Lithuania
- Prior art keywords
- heteroaromatic
- nmda receptor
- receptor modulators
- nmda
- modulators
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265182P | 2015-12-09 | 2015-12-09 | |
| PCT/US2016/065852 WO2017100591A1 (en) | 2015-12-09 | 2016-12-09 | Heteroaromatic nmda receptor modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3386591T true LT3386591T (lt) | 2020-10-12 |
Family
ID=57681781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP16820103.6T LT3386591T (lt) | 2015-12-09 | 2016-12-09 | Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10626122B2 (enExample) |
| EP (1) | EP3386591B1 (enExample) |
| JP (1) | JP7071917B2 (enExample) |
| CY (1) | CY1123359T1 (enExample) |
| DK (1) | DK3386591T3 (enExample) |
| ES (1) | ES2821010T3 (enExample) |
| HR (1) | HRP20201522T1 (enExample) |
| HU (1) | HUE051395T2 (enExample) |
| LT (1) | LT3386591T (enExample) |
| PL (1) | PL3386591T3 (enExample) |
| PT (1) | PT3386591T (enExample) |
| RS (1) | RS60834B1 (enExample) |
| SI (1) | SI3386591T1 (enExample) |
| SM (1) | SMT202000534T1 (enExample) |
| WO (1) | WO2017100591A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3386591T3 (da) | 2015-12-09 | 2020-09-28 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and uses thereof |
| US10500205B2 (en) | 2015-12-09 | 2019-12-10 | Cadent Therapeutics, Inc. | Thienopyrimidinone NMDA receptor modulators and uses thereof |
| CA3047403A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics, Inc. | Nmda receptor modulators and uses thereof |
| HUE062566T2 (hu) | 2018-08-03 | 2023-11-28 | Novartis Ag | Heteroaromás NMDA receptor modulátorok és alkalmazásaik |
| US11358971B2 (en) * | 2019-07-03 | 2022-06-14 | H. Lundbeck A/S | Prodrugs of modulators of the NMDA receptor |
| IN202011027502A (enExample) * | 2020-06-29 | 2021-12-31 | Council Scient Ind Res | |
| WO2025019109A1 (en) * | 2023-07-17 | 2025-01-23 | Neumora Therapeutics, Inc. | Modulators of nmda receptors and related products and methods |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1067079A (en) | 1976-07-22 | 1979-11-27 | Yamanouchi Pharmaceutical Co. | Nitrogen-containing heterobicyclic compounds |
| FR2549834B1 (fr) | 1983-07-25 | 1985-10-18 | Sanofi Sa | Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques |
| US4921854A (en) | 1986-12-30 | 1990-05-01 | Egis Gyogyszergyar | Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds |
| US5298502A (en) | 1988-12-12 | 1994-03-29 | Fmc Corporation | Method and composition for photodynamic treatment and detection of tumors |
| WO1994027975A1 (de) | 1993-05-21 | 1994-12-08 | Pentapharm Ag | 3-(mercaptoalkyl)- bzw. 3-(alkylthioalkyl)-pyrimidin-2,4 (1h, 3h)-dione |
| CA2257950A1 (en) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
| US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| WO2002000629A1 (en) | 2000-06-26 | 2002-01-03 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
| US6878743B2 (en) | 2001-09-18 | 2005-04-12 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
| AR038118A1 (es) | 2002-01-14 | 2004-12-29 | Upjohn Co | Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| CN101035765B (zh) | 2004-07-13 | 2010-10-13 | 弗·哈夫曼-拉罗切有限公司 | 磺酰胺衍生物 |
| TW200643015A (en) * | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
| US8618115B2 (en) | 2005-10-26 | 2013-12-31 | Bristol-Myers Squibb Company | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them |
| NZ575426A (en) | 2006-09-11 | 2010-09-30 | Organon Nv | Quinazolinone and isoquinolinone acetamide derivatives useful for the treatment of disorders which are influenced by modulation of the activity of the hpa axis |
| CA2663193A1 (en) | 2006-09-11 | 2008-03-20 | N.V. Organon | 2-(1-oxo-1h-isoquinolin-2-yl)acetamide derivatives |
| EP2425840B1 (en) | 2006-12-15 | 2015-04-08 | Abraxis BioScience, Inc. | Triazine derivatives and their therapeutical applications |
| EP1939187A1 (en) | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
| US8183276B2 (en) | 2007-02-08 | 2012-05-22 | Christian Fischer | Therapeutic agents |
| US9034907B2 (en) | 2007-04-18 | 2015-05-19 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2008138126A1 (en) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
| AU2008289573B2 (en) | 2007-08-21 | 2013-05-16 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| ES2586459T3 (es) | 2008-05-01 | 2016-10-14 | Glaxosmithkline Llc | Quinolinas y análogos relacionados como moduladores de sirtuina |
| MX2010012961A (es) | 2008-05-29 | 2011-03-03 | Sirtris Pharmaceuticals Inc Star | Imidazopiridina y analogos relacionados como moduladores de sirtuina. |
| EP2138494A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
| JP5758292B2 (ja) | 2008-07-03 | 2015-08-05 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュイン調節薬としてのベンズイミダゾールおよび関連する類似体 |
| CN101628913B (zh) | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| AU2009295946B2 (en) | 2008-09-29 | 2013-03-21 | Sirtris Pharmaceuticals, Inc. | Chromenone analogs as sirtuin modulators |
| HRP20150355T1 (hr) | 2009-01-12 | 2015-06-19 | Pfizer Limited | Sulfonamidni derivati |
| EP2411370B1 (en) | 2009-03-27 | 2015-04-22 | AbbVie Inc. | Compounds as cannabinoid receptor ligands |
| EP2264035A1 (en) | 2009-06-04 | 2010-12-22 | Merz Pharma GmbH & Co. KGaA | Glycine B antagonists |
| TW201116532A (en) | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| MX2012004289A (es) | 2009-10-13 | 2012-06-12 | Msd Oss Bv | Derivados de azina condensada para el tratamiento de enfermedades relacionadas con el receptor de acetilcolina. |
| JP5871897B2 (ja) | 2010-03-26 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジルトリアゾール |
| US9290507B2 (en) | 2010-03-26 | 2016-03-22 | Boehringer Ingelheim International Gmbh | B-RAF kinase inhibitors |
| EP2593106A4 (en) | 2010-07-16 | 2014-01-01 | Univ Rockefeller | ORGANIC CONNECTIONS |
| JP2013540145A (ja) | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤 |
| US20120165330A1 (en) | 2010-12-22 | 2012-06-28 | Sirtris Pharmaceuticals, Inc. | Quinazolinone and related analogs as sirtuin modulators |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| SI2707361T1 (sl) | 2011-05-10 | 2017-12-29 | Gilead Sciences, Inc. | Zlite heterociklične spojine kot modulatorji natrijevega kanala |
| WO2013048928A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| EP2760840B1 (en) | 2011-09-30 | 2015-08-12 | Bristol-Myers Squibb Company | Quinolinone carboxamide inhibitors of endothelial lipase |
| US8993557B2 (en) | 2011-09-30 | 2015-03-31 | Bristol-Myers Squibb Company | Pyridinedione carboxamide inhibitors of endothelial lipase |
| CN102336768A (zh) | 2011-10-24 | 2012-02-01 | 中国科学院上海有机化学研究所 | N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途 |
| TWI701253B (zh) | 2011-11-11 | 2020-08-11 | 美商基利阿波羅有限責任公司 | Ａｃｃ抑制劑及彼等之用途 |
| EA029542B1 (ru) | 2012-02-10 | 2018-04-30 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ПРОИЗВОДНЫЕ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ |
| WO2014066743A1 (en) | 2012-10-25 | 2014-05-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
| MX362582B (es) | 2013-06-28 | 2019-01-24 | Beigene Ltd | Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa. |
| WO2015007453A1 (en) | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| US20150141433A1 (en) | 2013-09-26 | 2015-05-21 | Mnemosyne Pharmaceuticals, Inc. | N-arylmethyl sulfonamide negative modulators of nr2a |
| PT3055315T (pt) | 2013-10-11 | 2018-10-25 | Hoffmann La Roche | Tiazolopirimidonas enquanto moduladores da atividade do recetor nmda |
| WO2015064714A1 (ja) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体 |
| CN103664877A (zh) | 2013-12-25 | 2014-03-26 | 重庆医药工业研究院有限责任公司 | 一种喹啉衍生物、其制备方法和应用 |
| EP3191459A1 (en) * | 2014-09-05 | 2017-07-19 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
| WO2016081649A1 (en) | 2014-11-18 | 2016-05-26 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto |
| UA120647C2 (uk) | 2015-04-15 | 2020-01-10 | Ф. Хоффманн-Ля Рош Аг | Піридопіримідинони та їх застосування як модуляторів рецептора n-метил-d-аспартату |
| KR20180102052A (ko) | 2015-10-16 | 2018-09-14 | 노오쓰웨스턴 유니버시티 | 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 |
| DK3386591T3 (da) | 2015-12-09 | 2020-09-28 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and uses thereof |
| US10500205B2 (en) | 2015-12-09 | 2019-12-10 | Cadent Therapeutics, Inc. | Thienopyrimidinone NMDA receptor modulators and uses thereof |
| WO2017188694A1 (ko) | 2016-04-25 | 2017-11-02 | 이뮤노메트테라퓨틱스 인코포레이티드 | 질소를 포함하는 헤테로아릴 화합물 및 이의 용도 |
| WO2018026371A1 (en) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
| CA3047403A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics, Inc. | Nmda receptor modulators and uses thereof |
| SMT202200011T1 (it) | 2017-09-27 | 2022-03-21 | Incyte Corp | Sali di derivati di pirrolotriazina utili come inibitori di tam |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| HUE062566T2 (hu) | 2018-08-03 | 2023-11-28 | Novartis Ag | Heteroaromás NMDA receptor modulátorok és alkalmazásaik |
-
2016
- 2016-12-09 DK DK16820103.6T patent/DK3386591T3/da active
- 2016-12-09 ES ES16820103T patent/ES2821010T3/es active Active
- 2016-12-09 WO PCT/US2016/065852 patent/WO2017100591A1/en not_active Ceased
- 2016-12-09 US US16/060,056 patent/US10626122B2/en active Active
- 2016-12-09 LT LTEP16820103.6T patent/LT3386591T/lt unknown
- 2016-12-09 SI SI201630931T patent/SI3386591T1/sl unknown
- 2016-12-09 PT PT168201036T patent/PT3386591T/pt unknown
- 2016-12-09 HR HRP20201522TT patent/HRP20201522T1/hr unknown
- 2016-12-09 EP EP16820103.6A patent/EP3386591B1/en active Active
- 2016-12-09 RS RS20201142A patent/RS60834B1/sr unknown
- 2016-12-09 SM SM20200534T patent/SMT202000534T1/it unknown
- 2016-12-09 JP JP2018529995A patent/JP7071917B2/ja active Active
- 2016-12-09 HU HUE16820103A patent/HUE051395T2/hu unknown
- 2016-12-09 PL PL16820103.6T patent/PL3386591T3/pl unknown
-
2020
- 2020-01-31 US US16/779,517 patent/US11236104B2/en active Active
- 2020-09-23 CY CY20201100895T patent/CY1123359T1/el unknown
-
2021
- 2021-12-14 US US17/550,435 patent/US12162890B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7071917B2 (ja) | 2022-05-19 |
| US20180362541A1 (en) | 2018-12-20 |
| SI3386591T1 (sl) | 2020-11-30 |
| US20210107916A1 (en) | 2021-04-15 |
| EP3386591B1 (en) | 2020-06-24 |
| WO2017100591A1 (en) | 2017-06-15 |
| SMT202000534T1 (it) | 2020-11-10 |
| EP3386591A1 (en) | 2018-10-17 |
| US12162890B2 (en) | 2024-12-10 |
| US20230023543A1 (en) | 2023-01-26 |
| HRP20201522T1 (hr) | 2020-12-11 |
| US11236104B2 (en) | 2022-02-01 |
| HUE051395T2 (hu) | 2021-03-01 |
| US10626122B2 (en) | 2020-04-21 |
| PT3386591T (pt) | 2020-10-01 |
| JP2018536685A (ja) | 2018-12-13 |
| RS60834B1 (sr) | 2020-10-30 |
| DK3386591T3 (da) | 2020-09-28 |
| CY1123359T1 (el) | 2021-12-31 |
| ES2821010T3 (es) | 2021-04-23 |
| PL3386591T3 (pl) | 2021-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807731B (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IL264514B (en) | Spiro-lactam nmda receptor modulators and their uses | |
| IL286107A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IL264488A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IL240166A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL240164A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL240163A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL240162A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL240165A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| ZA201800827B (en) | Substituted 4-azaindoles and their use as glun2b receptor modulators | |
| EP3490994B8 (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| LT3386591T (lt) | Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas | |
| IL254921A0 (en) | Pyridopyrimidinones and their uses as nmda receptor modulators | |
| IL280474B1 (en) | Heteroaromatic nmda receptor modulators and their uses |